Does anyone here look in depth at the numbers presented in this abstract? It is from a another presentation at ASCO and directly comes from the GALAXY-1 trial. Would be interested in what you think it may disclose of the GALAXY-1 results.
nubie.dubie, SNTA had previously talked about data in the Galaxy trial regarding Ganetespib's ability to dramatically block the formation of new metastatic lesions. I assume that is the abstract that has caught your interest.